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The emerging field of adoptive transfer of T lymphocytes holds a tremendous promise for the treatment of 
advanced therapy-resistant tumors1. Preclinical and animal studies have suggested that the clinical success rate 
of immunotherapy can be linked to T cell-related attributes such as longevity, proliferative potential and 
metabolism. In particular, less differentiated T lymphocyte subsets such as T stem and central memory cells 
show increased antitumor activity compared to effector T cells due to higher in vivo expansion rates and longer 
persistence in the recipient organism2. The nature of the infused T cell population is largely determined by the 
protocols used during the expansion. The vast majority of the currently reported methods for T cell culture are 
based on the use of high doses of IL-2 to maximize the growth rate of the cells, at the expense of vast 
differentiation towards the short-lived effector phenotype. Recently, several reports have identified the molecular 
mechanisms behind the progressive differentiation stages driving the development of T memory and effector 
subsets3. However, the conditions used for the formation and expansion of T memory subsets in vitro involve 
the use of poorly defined human serum components. Additionally, no real investigation of the physicochemical 
environment and engineering parameters for lymphocyte culture under serum free conditions has been 
reported. 
 
In order to develop a process that could generate T cells with improved antitumor efficacy in more defined 
conditions, we first identified the critical medium components capable of substituting the addition of serum. 
Secondly, we screened for signaling agonists and inhibitors in order to influence the pathways that drive 
differentiation towards memory or effector phenotypes. Lastly, a DoE approach was performed to evaluate the 
effect of growth enhancers and physicochemical variables to maximize the lymphocyte expansion rate. 
Our results demonstrate a valuable alternative to serum-supplemented media to generate large number of T 
cells with an early memory phenotype (CCR7+ CD27+) starting from unfractionated human CD3+ T 
lymphocytes. Moreover, this approach leads to growth rates comparable to standard protocols, with the 
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